What partnership with racer Mann means for Genetic Technologies Limited (ADR) (NASDAQ:GENE)
Genetic Technologies Limited (ADR) (NASDAQ:GENE) announced a partnership with Ms. Pippa Mann, an international race car driver. The deal hinged on Mann helping to raise the profile of Genetic Technologies’ sporadic breast cancer risk assessment test technology known as BREVAGenplus.
The agreement with Mann marked the first time Genetic Technologies Limited (ADR) (NASDAQ:GENE) entered a deal to promote BREVAGenplus nationally in the U.S. The reason for picking on Mann to help market BREVAGenplus is that officials of Genetic Technologies said she has shown strong commitment in reducing the effects of breast cancer on women. Mann does that may working closely with organizations and corporations focused on developing breast cancer treatments.
As part of the promotion agreement, Mann will participate in various BREVAGenplus events. She will also don apparels with BREVAGenplus logo.
According to Genetic Technologies Limited (ADR) (NASDAQ:GENE)’s CEO, BREVAGenplus is geared towards prevention and early detection of breast cancer.
RXi Pharmaceuticals Corp (NASDAQ:RXII) planning presentation at 18th Annual TIDES conference
Representatives of RXi Pharmaceuticals Corp (NASDAQ:RXII) will present at the 18th Annual TIDES event in California next month. The Annual TIDES event provides participants with the opportunity to access industry leaders and build partnerships that can be beneficial immediately or at a later time.
Through the conference, participants can also get ways to accelerate their product development program to shorten time to market and unlock the potential quickly. As for RXi Pharmaceuticals whose area is biotech, it will present at Annual TIDES’s Oligonucleotide and Peptides Therapeutics Conference.
Clinical and non-clinical presentations
Genetic Technologies Limited (ADR) (NASDAQ:GENE) will have two presentations on the same day at the Annual TIDES conference. The company’s Chief Development Officer, Pamela Pavco, will make the first presentation during the conference’s session on preclinical and clinical development strategies. In the presentation, Pavco will discuss the company’s candidate RXI-109, which is an sd-rxRNA targeted at connective tissue growth factor.
In the second presentation, RXi Pharmaceuticals’s VP of Research, Karen Bulock, will discuss the company’s non-clinical studies focused on dermal clinical program. The presentation by Bulock will take place during the conference’s session on non-clinical case studies in oligonucleotide development.
The 18th Annual TIDES event will take place from May 9 – 12 in Long Beach, California.
Regaining listing compliance
Genetic Technologies Limited (ADR) (NASDAQ:GENE) will be discussing its programs and seeking potential partners at the Annual TIDES event after it recently moved to clear a major listing headache. The company performed a reverse stock split whereby 10 shares were combined to make one share, thus lifting the minimum bid price of the stock. The move was important to ensure the company maintains its listing on NASDAQ Capital Market.
After RXi Pharmaceuticals’ share price fell below $1, it fell below NASDAQ’s listing requirement and the company was given until May 2 to regain compliance or risk delisting. As such, the board of RXi Pharmaceuticals took the opportunity to shrink the number of company’s outstanding shares, thus raising the minimum bid price to more than $2. The reverse stock split didn’t affect the company’s authorized shares, but help lift it out of potential doldrums.
The reason Genetic Technologies Limited (ADR) (NASDAQ:GENE) had to secure its NASDAQ listing by all means is that the board and the management considers it important for sourcing financing and other benefits.